Four in ten U.S. adults have skipped doses, delayed refills, or left a prescription unfilled because of cost, and six in ten now worry about affording their medications. Affordability is usually framed as a patient access issue, but it's also a financial one, with direct consequences for margins and reimbursement.
When a patient leaves with an unfilled prescription, the impact lands well beyond the pharmacy — in readmissions, denied claims, avoidable ED visits and payer penalties that rarely surface in traditional financial reporting.
This session makes the case for treating medication affordability as a shared financial strategy between pharmacy and revenue cycle, not a siloed access problem.
You’ll learn:
- How affordability failures create costs invisible in standard financial reporting
- Ways to improve capture of copay assistance, manufacturer and foundation funding
- Which shared metrics drive cross-functional accountability and financial performance
